Ottignies-Louvain-La-Neuve

• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 5 2024-04-12 Metastatic renal cell carcinoma (mRCC)
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
• MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex … Recruiting
  2024-514139-50-00 5 2022-11-14 Multiple myeloma
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 Adenocarcinoma of the prostate
• A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N … Ended recruitment
  2022-500802-16-00 5 2023-11-01 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung
• Safety and efficacy analysis of an antibody associated with a chemotherapy for patients with a triple negative metastatic breast cancer. Ended recruitment
  2022-502369-10-00 5 2023-10-02 Triple negative metastatic breast cancer
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• A study to test trimodulin in adult hospitalized patients with severe pneumonia Ended recruitment
  2022-501352-28-00 5 2023-06-07 Severe community-acquired pneumonia (sCAP)
• A study in metastatic breast cancer patients receiving eftilagimod alpha or placebo in combination with a standard chemotherapy (paclitaxel) Ended recruitment
  2024-511023-34-00 10 2023-05-05 HER2-neg/low metastatic breast cancer
• A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin … Ended recruitment
  2023-503467-41-00 5 2022-10-12 Relapsed or Refractory Multiple Myeloma
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can … Ended recruitment
  2023-503826-37-00 5 2022-02-11 Unresectable locally-advanced or metastatic HER2+ breast cancer
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved … Ended recruitment
  2023-506986-74-00 9 2021-12-27 B-cell non-Hodgkin lymphoma (NHL)
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended recruitment
  2023-506365-64-00 5 2020-10-16 Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
• TALAPRO 2: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT … Ended recruitment
  2023-509087-20-00 5 2019-04-16 Metastatic Castration-resistant Prostate Cancer
• A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Lo … Ended recruitment
  2024-511850-34-00 9 2019-01-02 Previously untreated locally recurrent inoperable or metastatic triple
• A Phase 3 Study of Zanubrutinib (BGB-3111) Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocyt … Ended recruitment
  2023-509976-40-00 5 2018-05-28 Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
• A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Ended recruitment
  2022-502798-40-00 5 2017-07-31 Patients with resected colon carcinoma
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended recruitment
  2023-509671-17-00 5 2017-07-12 Breast Cancer
• Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco … Ended recruitment
  2024-516996-34-00 5 2012-04-12 oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
• Phase 2 Study of CAL02 plus Standard of Care in Severe Community-Acquired Bacterial Pneumonia (SCABP) Halted
  2022-502049-91-00 4 2023-09-26 SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
• Phase 2b study to investigate the safety and efficacy of TIN816 in SA-AKI Ended
  2023-505903-22-00 4 2024-07-02 Sepsis associated acute kidney injury
• A study to test trimodulin in adult hospitalized patients with CAP including COVID-19 pneumonia. Ended
  2024-513002-60-00 5 2022-10-26 Non-severe community-acquired pneumonia (CAP) or moderate or severe Co
• DESTINY-Breast08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other thera … Ended
  2023-505690-33-00 3 2022-03-11 Metastatic Breast Cancer
• The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic … Ended
  2024-517251-12-00 5 2021-11-02 Recurrent or metastatic head and neck squamous cell carcinoma

Showing 25–48 of 49 trials